Unknown

Dataset Information

0

Post-Marketing Benefit-Risk Assessment of Rotavirus Vaccination in Japan: A Simulation and Modelling Analysis.


ABSTRACT:

Introduction

Rotarix™, GSK's live attenuated rotavirus vaccine, was introduced in Japan in 2011. A recent trend in reduction of rotavirus gastroenteritis (RVGE) due to this vaccine was described. However, an observed/expected analysis showed a temporal association with intussusception within 7 days post dose 1.

Objective

In this paper, we compare the benefit and risk of vaccination side-by-side in a benefit-risk analysis.

Methods

The number of vaccine-preventable RVGE-associated hospitalizations and deaths (benefit) and intussusception-associated hospitalizations and deaths (risk) following two doses of Rotarix™ in Japan was compared using simulations. Source data included peer-reviewed clinical and epidemiological publications, Japanese governmental statistics (Statistics Bureau, Ministry of Internal Affairs and Communications), and market survey data.

Results

For a birth cohort of 1 million vaccinated Japanese children followed for 5 years, the benefit-risk analysis suggested that the vaccine would prevent ~17,900 hospitalizations and ~6.3 deaths associated with RVGE. At the same time, vaccination would be associated with about ~50 intussusception hospitalizations and ~0.017 intussusception deaths. Therefore, for every intussusception hospitalization caused by vaccination and for one intussusception-associated death, 350 (95 % CI 69-2510) RVGE-associated hospitalizations and 366 (95 % CI 59-3271) RVGE-associated deaths are prevented, respectively, by vaccination.

Conclusions

The benefit-risk balance for Rotarix™ is favorable in Japan. From a public health perspective, the benefits in terms of prevented RVGE hospitalizations and deaths for the vaccinated population far exceed the estimated risks due to intussusception.

SUBMITTER: Ledent E 

PROVIDER: S-EPMC4749653 | biostudies-literature | 2016 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Post-Marketing Benefit-Risk Assessment of Rotavirus Vaccination in Japan: A Simulation and Modelling Analysis.

Ledent Edouard E   Lieftucht Alfons A   Buyse Hubert H   Sugiyama Keiji K   Mckenna Michael M   Holl Katsiaryna K  

Drug safety 20160301 3


<h4>Introduction</h4>Rotarix™, GSK's live attenuated rotavirus vaccine, was introduced in Japan in 2011. A recent trend in reduction of rotavirus gastroenteritis (RVGE) due to this vaccine was described. However, an observed/expected analysis showed a temporal association with intussusception within 7 days post dose 1.<h4>Objective</h4>In this paper, we compare the benefit and risk of vaccination side-by-side in a benefit-risk analysis.<h4>Methods</h4>The number of vaccine-preventable RVGE-assoc  ...[more]

Similar Datasets

| S-EPMC5878204 | biostudies-literature
| S-EPMC7148003 | biostudies-literature
| S-EPMC10430202 | biostudies-literature
| S-EPMC6423272 | biostudies-literature
| S-EPMC9535195 | biostudies-literature
| S-EPMC6130096 | biostudies-literature
| S-EPMC7441603 | biostudies-literature
| S-EPMC8576362 | biostudies-literature
| S-EPMC5797186 | biostudies-literature
| S-EPMC9290907 | biostudies-literature